HCA
DNLI icon

Harbor Capital Advisors’s Denali Therapeutics DNLI Stock Holding History

Harbor Capital Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-60,304
Closed -$1.29M – 773
2023
Q4 		$1.29M Buy
60,304
+8,025
+15% +$159K 0.25% 104
2023
Q3 		$1.08M Buy
52,279
+14,155
+37% +$359K 0.23% 114
2023
Q2 		$1.13M Buy
+38,124
New +$1.07M 0.23% 113

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Harbor Capital Advisors's DNLI Position: Q1 2024 in Review

Harbor Capital Advisors sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 60,304 shares — an estimated $1.29M sold.

Harbor Capital Advisors first reported a position in DNLI in Q2 2023 and held it in 3 quarters. The position peaked at $1.29M in Q4 2023. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Harbor Capital Advisors reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 60,304 Denali Therapeutics shares in Q1 2024, an estimated $1.29M.
  • Harbor Capital Advisors first reported a position in Denali Therapeutics in Q2 2023 and held it in 3 quarters.
  • Harbor Capital Advisors's Denali Therapeutics position peaked at $1.29M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Harbor Capital Advisors's 13F filing for Q1 2024, filed 13 May 2024.